Drug prices
Executive Summary
Average wholesale prices for the top 20 drugs prescribed in 1987 to persons under age 65 increased 82% between 1985 and 1991. The costs for top 20 drugs used by the elderly increased by an average of 79% during the same period, according to a study by Lewin-ICF that was released Sept. 10 by the advocacy organization Families USA. Greatest increases were for Norwich Eaton's decongestant/expectorant Entex LA (phenylpropanolamine HCl/guaifenesin), which increased 150% in price between 1986 and 1991. Wyeth-Ayerst's Premarin, Inderal (propranolol HCl) and Isordil (isosorbide dinitrate) rose 148%, 129% and 120%, respectively. PMA issued a same-day response noting that drugs account for .07 of the health dollar and pointing to moderating inflation as measured by the Producer Price Index.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth